Lacosamide Hikma (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This action stabilises hyper‑excitable neurons, reduces repetitive firing, and limits the spread of epileptic activity without markedly affecting normal neuronal conduction.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s clinical condition, age, renal function and concomitant therapies. Dosing recommendations are provided in the product’s prescribing information and should be followed exactly as directed by a qualified health professional.

Lacosamide’s pregnancy category is listed as unknown, meaning that potential risks to the fetus have not been fully established. Use during pregnancy or lactation should only occur when the expected benefit justifies the potential risk, and it should be discussed with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Compared with older sodium‑channel blockers such as carbamazepine, lacosamide selectively enhances slow inactivation rather than fast inactivation, offering a different safety profile and fewer drug‑interaction concerns. It is often chosen when patients need an alternative mechanism or have intolerance to other agents.

The product must be stored refrigerated at 2 °C to 8 °C, protected from light, and must not be frozen or shaken. Prior to administration, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration before use.

Lacosamide Hikma is given by intravenous injection or infusion. The preparation is administered slowly over several minutes under clinical supervision, using aseptic technique. The exact infusion rate and duration are determined by the prescribing physician and documented in the treatment protocol.

The most serious adverse events include cardiac arrhythmias such as atrioventricular block, severe skin reactions like Stevens‑Johnson syndrome, and respiratory depression. Patients should be monitored for ECG changes, skin eruptions and breathing difficulties, especially during the initial dosing period.

Lacosamide should be avoided in individuals with known hypersensitivity to the drug or its excipients, and in patients with severe cardiac conduction disorders (e.g., advanced AV block) unless close cardiac monitoring is possible. Caution is also advised for those with significant renal impairment.